Dexcom, Inc. 2021 Q3 Form 10-Q Summary
Business context and reporting period
Dexcom develops and sells continuous glucose monitoring (CGM) systems for diabetes management. This unaudited filing covers the quarter and nine months ended September 30, 2021, compared with the same periods in 2020. The company reports one operating segment.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $650.2 million | $500.9 million | $1,750.3 million | $1,357.8 million |
| Gross profit / margin | $446.9 million / 68.7% | $340.4 million / 68.0% | $1,207.9 million / 69.0% | $881.0 million / 64.9% |
| Operating income | $118.3 million | $94.1 million | $265.2 million | $195.5 million |
| Net income | $70.9 million | $72.2 million | $174.1 million | $138.4 million |
| Diluted earnings per share | $0.71 | $0.73 | $1.74 | $1.43 |
| Operating cash flow | Not separately stated for the quarter | Not separately stated for the quarter | $336.7 million | $303.6 million |
Q3 revenue increased 30% and operating income increased 26% year over year, while net income declined 2%. Nine-month revenue increased 29%, operating income 36%, and net income 26%. Nine-month cash flow from operations was $336.7 million; capital expenditures were $309.0 million. Cash, cash equivalents and short-term marketable securities totaled $2.70 billion at September 30, 2021, down $9.8 million from year-end 2020.
Total liabilities were $2.64 billion, including $1.70 billion carrying value of senior convertible notes. Their aggregate principal was $2.02 billion: $817.4 million due 2023 and $1.21 billion due 2025. The revolving credit facility had no borrowings and $193.6 million available, net of letters of credit. Current assets were $3.66 billion and current liabilities $734.9 million.
Material changes versus prior comparable periods
- Revenue growth was driven primarily by higher disposable sensor sales as the worldwide customer base expanded. Management said this was partly offset by greater U.S. pharmacy-channel volume at lower prices as the channel strategy evolved.
- Distributor sales rose to 85% of Q3 revenue from 76% a year earlier; direct sales fell to 15% from 24%. Outside-U.S. revenue increased to 25% of Q3 sales from 20%.
- Gross margin improved, which management attributed to revenue growth and manufacturing efficiencies. Operating expenses rose 33% in Q3: R&D increased 47%, primarily from software-related third-party and consulting costs and personnel; SG&A increased 26%, including higher payroll, marketing and legal costs.
- Q3 income tax expense was $19.8 million versus $2.9 million a year earlier, contributing to lower net income despite higher operating income. For the first nine months, the 7.7% effective tax rate reflected share-based compensation tax benefits and a one-time U.K. deferred-tax benefit; management estimated a 27.8% full-year 2021 tax rate.
- Inventory increased to $351.3 million from $234.7 million at December 31, 2020, and property and equipment, net, increased to $742.2 million from $515.3 million. The company recorded $31.6 million of acquisitions, net of cash acquired, and $23.4 million of net intangible assets related primarily to a customer-relationship asset.
Outlook, risks and unusual items
- No specific revenue or earnings guidance is provided in the supplied filing text. Management expects existing liquidity, operating cash flows and the available credit line to cover anticipated needs for at least the next 12 months. It notes quarterly revenue seasonality, typically with lower first-quarter sales than the preceding fourth quarter.
- Management plans continued investment in product development, manufacturing capacity, international expansion, and partnerships for insulin delivery and automated delivery systems. It is exploring additional CGM markets, including people with Type 2 diabetes and other populations.
- COVID-19-related uncertainty remained significant. Dexcom reported moderate operating disruptions and supply-chain disruption affecting development/manufacturing of its next-generation CGM product; further constraints, demand changes, clinical-trial delays and effects on customers’ insurance coverage could affect results.
- Dexcom and certain Abbott entities filed patent-infringement complaints against each other in multiple jurisdictions after a prior settlement and license agreement expired. The company says it intends to pursue its claims and defenses vigorously; the filing does not provide a clear estimate of possible financial exposure.
- Convertible-note conversions resulted in a $0.8 million debt-extinguishment loss in the first nine months of 2021. Notes are convertible under specified conditions; the 2023 notes were convertible at holders’ option through December 31, 2021 based on the stock-price trigger described in the filing.
- Key risks include pricing and reimbursement pressure, dependence on suppliers and manufacturing execution, competition, regulatory and product-liability exposure, privacy and cybersecurity, and the potential dilution, cash demands and other obligations associated with convertible debt.
Important facts for investors to verify
- Whether growth and gross-margin gains are sustainable, especially given lower-priced U.S. pharmacy-channel sales and increased distributor concentration.
- Whether the next-generation CGM product’s supply-chain and clinical-development delays affect launch timing or demand fulfillment.
- How the Abbott patent litigation progresses and whether it results in material costs, restrictions or other business impacts.
- The timing and potential dilution or cash-settlement effects of convertible-note conversions, alongside the notes’ maturity and credit-facility terms.
- Whether the estimated 27.8% full-year tax rate and the one-time U.K. deferred-tax benefit align with subsequent reported results.